Michel C van Harten1, Frank J P Hoebers2, Kenneth W Kross3, Erik D van Werkhoven4, Michiel W M van den Brekel5, Boukje A C van Dijk6. 1. Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: m.v.harten@nki.nl. 2. Department of Radiation Oncology (MAASTRO), Research Institute GROW, Maastricht University, Maastricht, The Netherlands. 3. Department of Otorhinolaryngology and Head and Neck Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands. 4. Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands. 5. Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Oral and Maxillofacial Surgery, Academic Medical Center, University of Amsterdam, The Netherlands; Department of Phonetic Sciences, University of Amsterdam, The Netherlands. 6. Department of Research, Comprehensive Cancer Centre The Netherlands (IKNL), Utrecht, The Netherlands; Department of Epidemiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Abstract
INTRODUCTION: Waiting to start treatment has been shown to be associated with tumor progression and upstaging in head and neck squamous cell carcinomas (HNSCCs). This diminishes the chance of cure and might lead to unnecessary mortality. We investigated the association between waiting times and survival in the Netherlands and assessed which factors were associated to longer waiting times. METHODS: Patient (age, sex, socioeconomic status (SES), tumor (site, stage) and treatment (type, of institute of diagnosis/treatment) characteristics for patients with HNSCC who underwent treatment were extracted from the Netherlands Cancer Registry (NCR) for 2005-2011. Waiting time was defined as the number of days between histopathological diagnosis and start of treatment. Univariable and multivariable Cox regression was used to evaluate survival. RESULTS: In total, 13,140 patients were included, who had a median waiting time of 37days. Patients who were more likely to wait longer were men, patients with a low SES, oropharynx tumors, stage IV tumors, patients to be treated with radiotherapy or chemoradiation, and patients referred for treatment to a Head and Neck Oncology Center (HNOC) from another hospital. The 5-year overall survival was 58% for all patients. Our multivariable Cox regression model showed that longer waiting time, was significantly related to a higher hazard of dying (p<0.0001). CONCLUSION: This is the first large population-based study showing that longer waiting time for surgery, radiotherapy or chemoradiation is a significant negative prognostic factor for HNSCC patients.
INTRODUCTION: Waiting to start treatment has been shown to be associated with tumor progression and upstaging in head and neck squamous cell carcinomas (HNSCCs). This diminishes the chance of cure and might lead to unnecessary mortality. We investigated the association between waiting times and survival in the Netherlands and assessed which factors were associated to longer waiting times. METHODS:Patient (age, sex, socioeconomic status (SES), tumor (site, stage) and treatment (type, of institute of diagnosis/treatment) characteristics for patients with HNSCC who underwent treatment were extracted from the Netherlands Cancer Registry (NCR) for 2005-2011. Waiting time was defined as the number of days between histopathological diagnosis and start of treatment. Univariable and multivariable Cox regression was used to evaluate survival. RESULTS: In total, 13,140 patients were included, who had a median waiting time of 37days. Patients who were more likely to wait longer were men, patients with a low SES, oropharynx tumors, stage IV tumors, patients to be treated with radiotherapy or chemoradiation, and patients referred for treatment to a Head and Neck Oncology Center (HNOC) from another hospital. The 5-year overall survival was 58% for all patients. Our multivariable Cox regression model showed that longer waiting time, was significantly related to a higher hazard of dying (p<0.0001). CONCLUSION: This is the first large population-based study showing that longer waiting time for surgery, radiotherapy or chemoradiation is a significant negative prognostic factor for HNSCC patients.
Authors: Luke H DeGraaff; Alexis J Platek; Austin J Iovoli; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Ryan P McSpadden; Moni Abraham Kuriakose; Wesley L Hicks; Mary E Platek; Anurag K Singh Journal: Oral Oncol Date: 2019-07-30 Impact factor: 5.337
Authors: A Andreano; M Ansarin; D Alterio; R Bruschini; M G Valsecchi; A G Russo Journal: Acta Otorhinolaryngol Ital Date: 2018-02 Impact factor: 2.124
Authors: Zeta Chow; Patrick Osterhaus; Bin Huang; Quan Chen; Nancy Schoenberg; Mark Dignan; B Mark Evers; Avinash Bhakta Journal: J Surg Res Date: 2020-10-20 Impact factor: 2.192
Authors: Sören Dahlke; Diana Steinmann; Hans Christiansen; Martin Durisin; Andre Eckardt; Gerd Wegener; Michael Bremer; Andreas Meyer Journal: In Vivo Date: 2017 Sep-Oct Impact factor: 2.155